HALP and mHALP as Effective Tools for 90-Day Mortality Prediction in Heart Failure
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background
Congestive heart failure (CHF) is a chronic syndrome with high mortality rates, necessitating risk stratification tools. Existing models are complex and may not incorporate crucial inflammatory and nutritional biomarkers. The Hemoglobin, Albumin, Lymphocyte, and Platelet (HALP) score and modified HALP (mHALP) score, which reflect nutritional status and systemic inflammation, emerged as potential prognostic tools. This study aimed to evaluate the predictive performance of HALP and mHALP scores for 90-day mortality in CHF patients.
Methods
This retrospective study utilized the MIMIC-IV database for 1000 adult CHF patients. HALP was calculated as [Hemoglobin (g/L) * Albumin (g/L) * Lymphocytes (/L)] / Platelets (/L), and mHALP by multiplying these components. The primary outcome was 90-day all-cause mortality. Univariate and multivariate logistic regression analyses were performed, and models were assessed using Receiver Operating Characteristic (ROC) analysis and Youden’s Index.
Results
Non-survivors (13.2%) had significantly lower median HALP (19.69 vs. 27.18) and mHALP (583,920.75 vs. 1,151,898.94) scores compared to survivors. In univariate analysis, HALP had an AUC of 0.63 and an OR of 0.25 for 90-day mortality, while mHALP showed a higher AUC of 0.68 and an OR of 0.22. After confounder adjusting, both log-transformed HALP (OR: 0.44) and mHALP (OR: 0.57) remained significant predictors of mortality. mHALP demonstrated better overall predictive performance.
Conclusion
Both HALP and mHALP scores are significantly associated with 90-day mortality in CHF patients, with mHALP exhibiting superior prediction. Easily calculable scores, derived from routine laboratory tests, offer a cost-effective, early risk stratification in CHF, potentially aiding in tailoring interventions.
